 SOUTH SAN FRANCISCO, Calif.--BUSINESS WIRE--Graphite Bio, Inc., a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced the pricing of its upsized initial public offering of 14,000,000 shares of its common stock at a price to the public of 17.00 per share. All of the shares of common stock are being offered by Graphite Bio. The gross proceeds to Graphite Bio from the offering, before 